| 초록 |
Anticancer chemo-immunotherapy has been widely studied from various field for complete eradication of malignant tumor. Recently, traditional anthracycline chemodrugs, such as Doxorubicin and Mitoxantrone, not only induce apoptosis of tumor cells but also elicit immunogenic cell death (ICD). ICD is main stimulating factor of initiating cancer-immunity cycle by releasing antigens. Released cancer cell antigens activates immune system, resulting infiltration of T cells into tumor tissue. Herein, we developed folate modified liposome for delivering both doxorubicin and indoximod simultaneously for enhanced anticancer chemo-immunotherapy. By interaction with folate receptor which are overexpressed in tumor, liposomes bearing dual agent can be easily uptaked. Doxorubicin elicit ICD while MPLA activate TLR4 pathway in antigen presenting cells, resulting enhanced anticancer chemo-immunotherapy |
